AXSOME THERAPEUTICS, INC. Research and Development Expense
AXSOME THERAPEUTICS, INC. (AXSM) reported Research and Development Expense of $46.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $46.23M, a 6.69% decline year-over-year.
- AXSOME THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $52.68M, a 17.62% increase year-over-year.
- AXSOME THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $48.79M, a 11.30% decline year-over-year.
- AXSOME THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $40.16M, a 11.51% decline year-over-year.
- AXSOME THERAPEUTICS, INC. research and development expense for fiscal 2025 was $183.28M, a 2.03% decline from fiscal 2024.
- AXSOME THERAPEUTICS, INC. research and development expense for fiscal 2024 was $187.08M, a 91.00% increase from fiscal 2023.
- AXSOME THERAPEUTICS, INC. research and development expense for fiscal 2023 was $97.94M, a 69.02% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. research and development expense for fiscal 2022 was $57.95M, a 0.20% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $46.23M 10-Q · filed 2026-08-10 | $98.90M 10-Q · filed 2026-08-10 | $147.69M derived: sum of 3 quarters · filed 2026-08-10 | $187.86M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $52.68M 10-Q · filed 2026-05-04 | $101.47M derived: sum of 2 quarters · filed 2026-05-04 | $141.63M derived: sum of 3 quarters · filed 2026-05-04 | $191.17M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-12-31 | $48.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $88.95M derived: sum of 2 quarters · filed 2026-02-23 | $138.49M derived: sum of 3 quarters · filed 2026-08-10 | $183.28M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | $40.16M 10-Q · filed 2025-11-03 | $89.70M derived: sum of 2 quarters · filed 2026-08-10 | $134.49M 10-Q · filed 2025-11-03 | $189.49M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-06-30 | $49.54M 10-Q · filed 2026-08-10 | $94.33M 10-Q · filed 2026-08-10 | $149.33M derived: sum of 3 quarters · filed 2026-08-10 | $194.72M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | $44.78M 10-Q · filed 2026-05-04 | $99.79M derived: sum of 2 quarters · filed 2026-05-04 | $145.18M derived: sum of 3 quarters · filed 2026-05-04 | $195.03M derived: sum of 4 quarters · filed 2026-05-04 | ||||
| 2024-12-31 | $55.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $100.39M derived: sum of 2 quarters · filed 2026-02-23 | $150.25M derived: sum of 3 quarters · filed 2026-02-23 | $187.08M 10-K · filed 2026-02-23 | ||||
| 2024-09-30 | $45.39M 10-Q · filed 2025-11-03 | $95.24M derived: sum of 2 quarters · filed 2025-11-03 | $132.07M 10-Q · filed 2025-11-03 | $162.87M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-06-30 | $49.85M 10-Q · filed 2025-08-04 | $86.68M 10-Q · filed 2025-08-04 | $117.49M derived: sum of 3 quarters · filed 2026-02-23 | $146.25M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-03-31 | $36.83M 10-Q · filed 2025-05-05 | $67.63M derived: sum of 2 quarters · filed 2026-02-23 | $96.40M derived: sum of 3 quarters · filed 2026-02-23 | $116.98M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2023-12-31 | $30.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $59.57M derived: sum of 2 quarters · filed 2026-02-23 | $80.15M derived: sum of 3 quarters · filed 2026-02-23 | $97.94M 10-K · filed 2026-02-23 | ||||
| 2023-09-30 | $28.77M 10-Q · filed 2024-11-12 | $49.35M derived: sum of 2 quarters · filed 2024-11-12 | $67.14M 10-Q · filed 2024-11-12 | $81.83M derived: sum of 4 quarters · filed 2025-02-18 | ||||
| 2023-06-30 | $20.58M 10-Q · filed 2024-08-05 | $38.37M 10-Q · filed 2024-08-05 | $53.07M derived: sum of 3 quarters · filed 2025-02-18 | $67.94M derived: sum of 4 quarters · filed 2025-02-18 | ||||
| 2023-03-31 | $17.79M 10-Q · filed 2024-05-06 | $32.49M derived: sum of 2 quarters · filed 2025-02-18 | $47.36M derived: sum of 3 quarters · filed 2025-02-18 | $63.16M derived: sum of 4 quarters · filed 2025-02-18 | ||||
| 2022-12-31 | $14.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $29.57M derived: sum of 2 quarters · filed 2025-02-18 | $45.36M derived: sum of 3 quarters · filed 2025-02-18 | $57.95M 10-K · filed 2025-02-18 | $57.95M 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $14.88M 10-Q · filed 2023-11-06 | $14.88M 10-Q · filed 2022-11-07 | $30.67M derived: sum of 2 quarters · filed 2023-11-06 | $43.25M 10-Q · filed 2023-11-06 | $43.25M 10-Q · filed 2022-11-07 | $57.04M derived: sum of 4 quarters · filed 2024-02-23 | ||
| 2022-06-30 | $15.79M 10-Q · filed 2023-08-07 | $15.79M 10-Q · filed 2022-08-09 | $28.38M 10-Q · filed 2023-08-07 | $28.38M 10-Q · filed 2022-08-09 | $42.16M derived: sum of 3 quarters · filed 2024-02-23 | $55.34M derived: sum of 4 quarters · filed 2024-02-23 | ||
| 2022-03-31 | $12.59M 10-Q · filed 2023-05-09 | $12.59M 10-Q · filed 2022-05-02 | $26.37M derived: sum of 2 quarters · filed 2024-02-23 | $39.55M derived: sum of 3 quarters · filed 2024-02-23 | $54.05M derived: sum of 4 quarters · filed 2024-02-23 | |||
| 2021-12-31 | $13.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $26.96M derived: sum of 2 quarters · filed 2024-02-23 | $41.47M derived: sum of 3 quarters · filed 2024-02-23 | $58.06M 10-K · filed 2024-02-23 | $58.06M 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $13.18M 10-Q · filed 2022-11-07 | $27.68M derived: sum of 2 quarters · filed 2022-11-07 | $44.28M 10-Q · filed 2022-11-07 | $61.66M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | $14.50M 10-Q · filed 2022-08-09 | $31.10M 10-Q · filed 2022-08-09 | $48.48M derived: sum of 3 quarters · filed 2023-02-28 | $63.28M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | $16.60M 10-Q · filed 2022-05-02 | $33.98M derived: sum of 2 quarters · filed 2023-02-28 | $48.78M derived: sum of 3 quarters · filed 2023-02-28 | $59.32M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $17.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $32.18M derived: sum of 2 quarters · filed 2023-02-28 | $42.72M derived: sum of 3 quarters · filed 2023-02-28 | $70.24M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $14.80M 10-Q · filed 2021-11-08 | $25.34M derived: sum of 2 quarters · filed 2021-11-08 | $52.86M 10-Q · filed 2021-11-08 | $72.07M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | $10.54M 10-Q · filed 2021-08-09 | $38.06M 10-Q · filed 2021-08-09 | $57.27M derived: sum of 3 quarters · filed 2022-03-01 | $73.11M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | $27.52M 10-Q · filed 2021-05-10 | $46.73M derived: sum of 2 quarters · filed 2022-03-01 | $62.56M derived: sum of 3 quarters · filed 2022-03-01 | $73.57M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | $19.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $35.04M derived: sum of 2 quarters · filed 2022-03-01 | $46.04M derived: sum of 3 quarters · filed 2022-03-01 | $53.65M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $15.84M 10-Q · filed 2020-11-05 | $26.84M derived: sum of 2 quarters · filed 2020-11-05 | $34.44M 10-Q · filed 2020-11-05 | $41.59M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $11.00M 10-Q · filed 2020-08-10 | $18.61M 10-Q · filed 2020-08-10 | $25.76M derived: sum of 3 quarters · filed 2021-03-01 | $31.80M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $7.60M 10-Q · filed 2020-05-11 | $14.75M derived: sum of 2 quarters · filed 2021-03-01 | $20.80M derived: sum of 3 quarters · filed 2021-03-01 | $26.35M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $7.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $13.19M derived: sum of 2 quarters · filed 2021-03-01 | $18.74M derived: sum of 3 quarters · filed 2021-03-01 | $23.50M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $6.04M 10-Q · filed 2019-11-07 | $11.59M derived: sum of 2 quarters · filed 2019-11-07 | $16.34M 10-Q · filed 2019-11-07 | $20.84M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-06-30 | $5.55M 10-Q · filed 2019-08-08 | $10.30M 10-Q · filed 2019-08-08 | $14.80M derived: sum of 3 quarters · filed 2020-03-12 | $19.27M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-03-31 | $4.75M 10-Q · filed 2019-05-09 | $9.25M derived: sum of 2 quarters · filed 2020-03-12 | $13.72M derived: sum of 3 quarters · filed 2020-03-12 | $18.72M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2017-12-31 | $4.49M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $8.97M derived: sum of 2 quarters · filed 2020-03-12 | $13.97M derived: sum of 3 quarters · filed 2020-03-12 | $19.96M 10-K · filed 2020-03-12 | ||||
| 2017-09-30 | $4.47M 10-Q · filed 2018-11-09 | $9.48M derived: sum of 2 quarters · filed 2018-11-09 | $15.46M 10-Q · filed 2018-11-09 | $21.27M derived: sum of 4 quarters · filed 2019-03-15 | ||||
| 2017-06-30 | $5.01M 10-Q · filed 2018-08-08 | $10.99M 10-Q · filed 2018-08-08 | $16.80M derived: sum of 3 quarters · filed 2019-03-15 | $22.37M derived: sum of 4 quarters · filed 2019-03-15 | ||||
| 2017-03-31 | $5.99M 10-Q · filed 2018-05-08 | $11.79M derived: sum of 2 quarters · filed 2019-03-15 | $17.36M derived: sum of 3 quarters · filed 2019-03-15 | $22.66M derived: sum of 4 quarters · filed 2019-03-15 | ||||
| 2016-12-31 | $5.81M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $11.38M derived: sum of 2 quarters · filed 2019-03-15 | $16.67M derived: sum of 3 quarters · filed 2019-03-15 | $21.20M 10-K · filed 2019-03-15 | ||||
| 2016-09-30 | $5.57M 10-Q · filed 2017-11-08 | $10.87M derived: sum of 2 quarters · filed 2017-11-08 | $15.39M 10-Q · filed 2017-11-08 | $17.60M derived: sum of 4 quarters · filed 2018-03-07 | ||||
| 2016-06-30 | $5.30M 10-Q · filed 2017-08-09 | $9.82M 10-Q · filed 2017-08-09 | $12.03M derived: sum of 3 quarters · filed 2018-03-07 | $13.56M derived: sum of 4 quarters · filed 2018-03-07 | ||||
| 2016-03-31 | $4.53M 10-Q · filed 2017-05-09 | $6.73M derived: sum of 2 quarters · filed 2018-03-07 | $8.26M derived: sum of 3 quarters · filed 2018-03-07 | $9.89M derived: sum of 4 quarters · filed 2018-03-07 | ||||
| 2015-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $3.73M derived: sum of 2 quarters · filed 2018-03-07 | $5.36M derived: sum of 3 quarters · filed 2018-03-07 | $6.78M 10-K · filed 2018-03-07 | ||||
| 2015-09-30 | $1.52M 10-Q · filed 2016-11-14 | $3.15M derived: sum of 2 quarters · filed 2016-11-14 | $4.57M 10-Q · filed 2016-11-14 | |||||
| 2015-06-30 | $1.63M 10-Q · filed 2016-08-09 | $3.04M 10-Q · filed 2016-08-09 | ||||||
| 2015-03-31 | $1.42M 10-Q/A · filed 2016-08-09 | |||||||
| 2014-12-31 | $4.28M 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |